Interleukin‐6 serum levels in patients with multiple myeloma
- 1 February 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 86 (2) , 439-440
- https://doi.org/10.1111/j.1365-2141.1994.tb04765.x
Abstract
Studying the prognostic value of serum interleukin-6 (IL-6) levels in multiple myeloma, we observed important daily variations in some patients. Therefore a unique serum IL-6 measurement should be interpreted with caution and requires confirmation by multiple determinations performed over a period of several days.Keywords
This publication has 12 references indexed in Scilit:
- Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment]Blood, 1992
- Measuring cytokine levels in bloodJournal of Immunological Methods, 1992
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging systemBlood, 1992
- Are serum interleukin-6 levels always useful for differentiating monoclonal gammopathies in unselected patients? [letter; comment] [see comments]Blood, 1992
- Sensitive ELISA for interleukin-6Journal of Immunological Methods, 1991
- The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with MyelomaLeukemia & Lymphoma, 1991
- Biological and clinical aspects of interleukin 6Immunology Today, 1990
- Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta.The Journal of Immunology, 1990
- Interleukin-6 and the acute phase responseBiochemical Journal, 1990
- Molecular cloning and expression of hybridoma growth factor in Escherichia coli.The Journal of Immunology, 1987